Across TCGA pan-cancer cohorts, CLPSL1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLPSL1 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CLPSL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLPSL1 expression acts as an unfavorable survival marker.

BLCA, LIHC, and ACC are the cancer types where CLPSL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.149	0.710	<.001	36	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CLPSL1 tumor-vs-normal RNA expression · all CLPSL1 data types